Business
Further re Aivlosin research
Further re Aivlosin research.
About this update from Eco Animal Health Group Plc
[{"type":"text","content":"\n May 2009\n\n\n ECO Animal Health Group plc\n\n Further re: Aivlosin® research\n\n\nDr David Brown and his team at the Virology Division of the Department of\nPathology at the University of Cambridge have been awarded a grant of £500,000\nby the Medical Research Council to investigate the inhibition of influenza\nviruses by macrolide antibiotics.\n\nDuring earlier studies funded by Eco Animal Health (Eco), it has been discovered\nthat Aivlosin®, Eco's patented macrolide antibiotic, appears to prevent the\nreplication of certain common viruses including influenza in laboratory test\nsystems without damaging cell cultures.\n\nEco and the University of Cambridge entered a collaborative research agreement\nin 2006 to investigate these new potential indications for Aivlosin® which is\ncurrently licensed for respiratory and enteric bacterial diseases in pigs and\npoultry.\n\nThese unexpected findings have formed the basis of patent filings as well as Eco\nand Cambridge Enterprise, the University's commercialisation office, signing\nlicensing agreements to jointly exploit these discoveries.\n\n\nContacts:\nECO Animal Health Group plc Marc Loomes 020 8447 8899\n\nSpiro Financial Anthony Spiro 020 8336 6196\n\nCenkos Securities plc Stephen Keys 020 7397 8926\n(Nominated Adviser) Elizabeth Bowman 020 7397 8928\n\n\nECO Animal Health Group plc is a leader in the development, registration and\nmarketing of pharmaceutical products for animals. Our products for these global\ngrowth markets promote well-being. Our financial goals are achieved through the\ncareful and responsible application of science to generate value for our\nshareholders. \n ","length":2030,"tagName":"div"}]